As of Jan 17, 2025, Edwards Lifesciences Corporation's Discounted Cash Flow (DCF) valuation estimates its share price at $38.9. This suggests it may be overvalued by (44.2%) compared to its current price of around $69.8, using a WACC of 9.6% and growth rates of 3.0%.
As of Jan 17, 2025, Edwards Lifesciences Corporation's Weighted Average Cost of Capital (WACC) is approximately 9.6%.
As of Jan 17, 2025, Edwards Lifesciences Corporation's Enterprise Value (EV) is approximately $22.3B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.